Share:
SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has joined the FLAMIN-GO Project consortium of academic and industry leaders in rheumatology, autoimmune disease research, and drug discovery and development to create an organ-on-a-chip solution toward personalized care and improved outcomes for rheumatoid arthritis (RA) patients.
Organ-on-a-chip refers to a microfluidic culture device that simulates the microarchitecture and functions of living human organs, potentially offering an alternative to traditional animal testing.
RA, an autoimmune inflammatory disorder characterized by synovial joint inflammation, affects ~0.5 to 1 percent of the global population. RA is a significant public health problem as it can lead to permanent disability. To gain insights into this disease, FLAMIN-GO Project
REGENHU announces its participation in the FLAMIN-GO project aimed at developing personalized treatments against rheumatoid arthritis
REGENHU today announced its participation in the FLAMIN-GO research project aimed at developing an organ-on-chip technology for clinical trials on Rheumatoid Arthritis (RA).
FLAMIN-GO is an EU-funded project featuring a strong, well-balanced composition of hospital, academia, and industry partners which brings together the know-how of experts in the fields of rheumatology, material science, tissue engineering, nanotechnology, cell biology, and 3D modeling, in a cohesive, transdisciplinary, multi-sectorial approach. The objective is to develop a personalized next-generation synovia-on-chip, that, by effectively mimicking the complexity of an RA joint, will enable personalized clinical trials-on-chip, and ultimately open new avenues toward personalized care in RA.